A new study, conducted in Europe, found the medicine worked just as well as an earlier disputed study, sponsored by ImClone Systems, said it did.
Doctors concluded Erbitux, the cancer drug that enmeshed ImClone Systems in an insider trading scandal, worked just as well as an earlier company-sponsored study said it did.